Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services [Yahoo! Finance]
Verrica Pharmaceuticals Inc. (VRCA)
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-Code (J7354) for YCANTH™, which is the only FDA-approved treatment for molluscum contagiosum. Under the Healthcare Common Procedure Coding System (HCPCS) process, the J-Code for YCANTH™ will become fully published April 1, 2024. “By securing a permanent J-Code for YCANTH, we have successfully reached a critical milestone in our commercial strategy that we expect will help us accelerate YCANTH utilization among the U.S. Medicaid and Medicare patient populations,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals. “In addition to greater patient access, we also anticipate a permanent J-Code will result in a more streamlined billing and reimbursement process for YCANTH.” J-codes are a type of HCPCS Level II code commonly used to designate non-orally administered dr
Show less
Read more
Impact Snapshot
Event Time:
VRCA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRCA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRCA alerts
High impacting Verrica Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VRCA
News
- Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss [Yahoo! Finance]Yahoo! Finance
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA [Yahoo! Finance]Yahoo! Finance
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAGlobeNewswire
VRCA
Earnings
- 2/29/24 - Miss
VRCA
Sec Filings
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- 4/19/24 - Form DEF
- VRCA's page on the SEC website